onc Videos

Videos

Mafalda Oliviera, MD, PhD, Vall d'Hebron University Hospital

Videos

Camizestrant for ER-Positive, HER2-Negative, Metastatic Breast Cancer

12/21/2022

At the 2022 San Antonio Breast Cancer Symposium, Mafalda Oliviera, MD, PhD, discusses results from the SERENA-2 trial, investigating camizestrant for ER-positive, HER-2 negative, metastatic breast cancer that had progressed on endocrine...

At the 2022 San Antonio Breast...

12/21/2022

Oncology

Seth Wander, MD, PhD, Massachusetts General Hospital

Videos

Genomic and Molecular Mechanisms of Resistance to CDK4/6 Inhibitors

12/21/2022

Seth Wander MD, PhD, discusses research presented at the 2022 San Antonio Breast Cancer Symposium, focusing on the genomic and molecular mechanisms of resistance to CDK4/6 inhibitors and antiestrogens in metastatic breast cancer.

Seth Wander MD, PhD, discusses...

12/21/2022

Oncology

Videos

First-Line Ibrutinib Plus Venetoclax for Patients With CLL: Video Roundtable

12/21/2022

Jan Burger, MD, PhD; Nitin Jain, MD; and Alessandra Ferrajoli, MD, discuss 4-year follow-up data from a phase 2 trial exploring combined ibrutinib and venetoclax for the first-line treatment of patients with CLL.

Jan Burger, MD, PhD; Nitin Jain,...

12/21/2022

Oncology

Videos

Adding Ibrutinib to Induction or Maintenance With or Without AutoHSCT Shows Strong Efficacy, Acceptable Toxicity in MCL

12/21/2022

Martin Dreyling, MD, discusses data from the Triangle trial showing strong efficacy and acceptable safety with the addition of ibrutinib to induction or maintenance treatment with or without autoHSCT in younger patients with MCL.

Martin Dreyling, MD, discusses...

12/21/2022

Oncology

Videos

Lasofoxifene for Targeting ESR1 Mutant in Breast Cancer After CDK4/6 Inhibition

12/21/2022

At the 2022 San Antonio Breast Cancer Symposium, Matthew Goetz, MD, discusses a translational end point from the ELAINE-1 trial, examining patient outcomes for HR-positive, HER2-negative breast cancer with an ESR1 mutation treated with...

At the 2022 San Antonio Breast...

12/21/2022

Oncology

Erika Hamilton, MD, Sarah Cannon Research Institute

Videos

Trastuzumab Deruxtecan Plus Pertuzumab in the First-Line Setting for Patients With Metastatic HER2-Positive Breast Cancer

12/21/2022

Erika Hamilton reviews updated results from a trial investigating trastuzumab deruxtecan alone and in different combinations, notably with pertuzumab, in the first-line setting for patients with metastatic HER2-positive breast cancer.

Erika Hamilton reviews updated...

12/21/2022

Oncology

Joseph Sparano, MD, Tisch Cancer Institute

Videos

Efficacy of Endocrine Therapy Alone for Patients with ER-Positive, HER2-Negative Breast Cancer

12/20/2022

At the 2022 San Antonio Breast Cancer Symposium, Joseph Sparano, MD, discusses the efficacy of endocrine therapy alone for patients with ER-positive, HER2-negative, lymph node-negative breast cancer.

At the 2022 San Antonio Breast...

12/20/2022

Oncology

Gary Deng, MD, Memorial Sloan Kettering Cancer Center

Videos

Complementary Medicine for Patients With Gastrointestinal Malignancies

12/20/2022

At the 2022 Great Debates & Updates in Gastrointestinal Malignancies virtual meeting, Gary Deng, MD, discusses modes of complementary medicine that patients with gastrointestinal cancers may be curious about.

At the 2022 Great Debates &...

12/20/2022

Oncology

Videos

Ruxolitinib in Patients With Myelofibrosis Who Had Anemia or Thrombocytopenia: Real-World Outcomes

12/20/2022

Srdan Verstovsek, MD, presents data on real-world outcomes of the use of ruxolitinib in patients with myelofibrosis who had anemia or thrombocytopenia at the ASH 2022 Meeting in New Orleans, LA.

Srdan Verstovsek, MD, presents...

12/20/2022

Oncology

Srikala Sridhar, MD, Princess Margaret Cancer Center

Videos

Impact of COVID-19 on Treatment of Patients With Metastatic Hormone Sensitive Prostate Cancer

12/20/2022

Srikala Sridhar, MD, shares insights from a study investigating how metastatic hormone sensitive prostate cancer care has changed during the COVID-19 pandemic.

Srikala Sridhar, MD, shares...

12/20/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology